Investing.com - Merck&Co reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Merck&Co announced earnings per share of $1.8 on revenue of $13.52B. Analysts polled by Investing.com anticipated EPS of $1.52 on revenue of $13.14B.
Merck&Co shares are up 7% from the beginning of the year, still down 10.27% from its 52 week high of $91.40 set on November 4, 2021. They are outperforming the S&P 500 which is down 3.71% from the start of the year.
Merck&Co follows other major Healthcare sector earnings this month
Merck&Co's report follows an earnings beat by J&J on January 25, who reported EPS of $2.13 on revenue of $24.8B, compared to forecasts EPS of $2.12 on revenue of $25.28B.
UnitedHealth had beat expectations on January 19 with fourth quarter EPS of $4.48 on revenue of $73.74B, compared to forecast for EPS of $4.3 on revenue of $72.98B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar